fluconazole has been researched along with Hematologic Malignancies in 56 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i." | 9.12 | An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006) |
| "A 7-year retrospective analysis of candidemia in patients with hematologic malignancies demonstrated that ten patients, who received itraconazole and fluconazole during neutropenia, developed breakthrough fungemia caused by fluconazole-resistant Candida albicans (C." | 7.73 | Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. ( Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T, 2006) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 5.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| "5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i." | 5.12 | An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006) |
| "A 7-year retrospective analysis of candidemia in patients with hematologic malignancies demonstrated that ten patients, who received itraconazole and fluconazole during neutropenia, developed breakthrough fungemia caused by fluconazole-resistant Candida albicans (C." | 3.73 | Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. ( Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T, 2006) |
| "Candida krusei is inherently resistant to fluconazole and is emerging as a frequent cause of fungemia in patients with hematologic malignant neoplasms." | 3.70 | Candida krusei fungemia. An escalating serious infection in immunocompromised patients. ( Abbas, J; Abi-Said, D; Bodey, GP; Girgawy, E; Hachem, R; Hanna, HA; Mardani, M; Raad, I; Whimbey, E, 2000) |
| "0 L and the bioavailability (F) was 81." | 2.90 | Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ( Ding, XL; Liu, LN; Miao, LY; Tian, JX; Xue, L; Yan, HH; Zhang, JJ; Zhang, WJ; Zhang, WW, 2019) |
| "Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients." | 2.73 | Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. ( Asakura, S; Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, KI; Miyata, A; Nawa, Y; Saito, T; Shinagawa, K; Sunami, K; Tabayashi, T; Tanimoto, M; Yano, T, 2008) |
| "If fluconazole was administered orally, blood samples were drawn 2, 8, and 24 hr after ingestion of the drug." | 2.70 | Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. ( Chiba, S; Hirai, H; Hirate, J; Kami, M; Kanda, Y; Kojima, N; Mori, S; Moriya, A; Saito, T; Sawada, Y; Yuji, K, 2001) |
| "In neutropenic patients with hematologic malignancies, prophylaxis with fluconazole significantly decreased fungal isolation and other indicators of fungal infection when compared with amphotericin B." | 2.69 | Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. ( Fujimori, Y; Kakishita, E; Kanamaru, A; Okada, M; Okamoto, T; Takatsuka, H; Takemoto, Y; Tamura, S; Wada, H, 1999) |
| " Itraconazole has a broader spectrum of activity but the capsules give erratic bioavailability in neutropenic patients." | 2.69 | A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. ( Morgenstern, GR; Prentice, AG; Prentice, HG; Ropner, JE; Schey, SA; Warnock, DW, 1999) |
| "Fluconazole was discontinued when a neutrophil count above 1." | 2.69 | Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. ( Goranov, S; Grudeva-Popova, J; Spasov, E; Vakrilov, V, 1999) |
| "Fluconazole prophylaxis was given to 12 patients for a mean of 21." | 2.69 | Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. ( Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, D; van Loenen, AC; Zweegman, S, 2000) |
| "The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs." | 2.66 | Breakthrough invasive fungal infections: Who is at risk? ( Chen, SC; Cornely, OA; Hoenigl, M; Jenks, JD; Thompson, GR, 2020) |
| "Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies." | 2.55 | [Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review]. ( Li, Y; Yu, L, 2017) |
| "The fungal esophagitis in patients with hematologic malignancies was not rare." | 1.43 | [A clinical study of fungal esophagitis in 13 patients with hematologic malignancies]. ( Ai, H; Li, YF; Liu, YY; Mi, RH; Song, YP; Wei, XD; Zhang, LN; Zhou, YL, 2016) |
| "Dose reductions of 50-75% for both sirolimus and tacrolimus, in combination with standard dosing of azole antifungal agents, were necessary to achieve therapeutic drug concentrations for immunosuppressants and potentially avoid toxicities." | 1.42 | Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. ( Fung, HC; Peksa, GD; Schultz, K, 2015) |
| "Most subjects (62%) had hematologic malignancies." | 1.39 | Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. ( Lloyd, L; Meibohm, A; Schuster, MG; Strom, B, 2013) |
| "Patients with oral mucositis assessment scale scores <20 had higher colonization rates than those with higher scores." | 1.39 | Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients. ( Freytes, CO; Kirkpatrick, WR; Patterson, TF; Redding, SW; Toro, JJ; Westbrook, SD; Wiederhold, NP, 2013) |
| "Oral cheek mucosal specimens from 52 cancer patients receiving chemotherapy were cultured on CHROMagar Candida plates for Candida identification." | 1.35 | Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. ( Lafleur, MD; Qi, C; Qi, QG; Sun, J, 2009) |
| "Fluconazole was given to 17 paitents, intraconazole was given to 21 patients, and intraconazole to the other 9 patients after they had no effect with fluconazole." | 1.35 | [Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies]. ( Chen, SP; Shu, YG; Xu, YJ; Zhu, Y, 2008) |
| "Neutropenia was the leading risk factor for all candidemia, whereas the catheter was the leading risk factor for C." | 1.35 | The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. ( Hachem, R; Hanna, H; Jiang, Y; Kontoyiannis, D; Raad, I, 2008) |
| "Mucormycoses were diagnosed in six patients, (median age of 52 years; range, 26-74) treated between 2001-2004." | 1.33 | Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. ( Bethge, WA; Einsele, H; Hebart, H; Horger, M; Kanz, L; Kröber, SM; Schmalzing, M; Schumacher, U; Stuhler, G, 2005) |
| "Cryptococcosis in patients with hematologic malignancies is a rare complication." | 1.32 | Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. ( Caira, M; Caramatti, C; Cinieri, S; D'Antonio, D; Del Favero, A; Fianchi, L; Girmenia, C; Martino, B; Martino, P; Masini, L; Melillo, L; Pagano, L; Todeschini, G, 2004) |
| "Fluconazole was effective as a single agent in 3 patients with solid tumors." | 1.31 | Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. ( Hachem, R; Minari, A; Raad, I, 2001) |
| " krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 1.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (10.71) | 18.2507 |
| 2000's | 34 (60.71) | 29.6817 |
| 2010's | 14 (25.00) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Effron, G | 1 |
| Kontoyiannis, DP | 1 |
| Lewis, RE | 1 |
| Perlin, DS | 1 |
| Xue, L | 1 |
| Zhang, WJ | 1 |
| Tian, JX | 1 |
| Liu, LN | 1 |
| Yan, HH | 1 |
| Zhang, WW | 1 |
| Ding, XL | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| Kanda, Y | 3 |
| Kimura, SI | 1 |
| Iino, M | 1 |
| Fukuda, T | 1 |
| Sakaida, E | 1 |
| Oyake, T | 1 |
| Yamaguchi, H | 1 |
| Fujiwara, SI | 1 |
| Jo, Y | 1 |
| Okamoto, A | 1 |
| Fujita, H | 1 |
| Takamatsu, Y | 1 |
| Saburi, Y | 1 |
| Matsumura, I | 1 |
| Yamanouchi, J | 1 |
| Shiratori, S | 1 |
| Gotoh, M | 1 |
| Nakamura, S | 1 |
| Tamura, K | 1 |
| Jenks, JD | 1 |
| Cornely, OA | 1 |
| Chen, SC | 1 |
| Thompson, GR | 1 |
| Hoenigl, M | 1 |
| Li, Y | 1 |
| Yu, L | 1 |
| Tang, L | 1 |
| Yang, XF | 1 |
| Qiao, M | 1 |
| Zhang, L | 1 |
| Tang, XW | 1 |
| Qiu, HY | 1 |
| Wu, DP | 1 |
| Sun, AN | 1 |
| Kung, HC | 1 |
| Johnson, MD | 1 |
| Drew, RH | 1 |
| Saha-Chaudhuri, P | 1 |
| Perfect, JR | 1 |
| Peksa, GD | 1 |
| Schultz, K | 1 |
| Fung, HC | 1 |
| Vuichard, D | 1 |
| Weisser, M | 1 |
| Orasch, C | 1 |
| Frei, R | 1 |
| Heim, D | 1 |
| Passweg, JR | 1 |
| Widmer, AF | 1 |
| Zhou, YL | 1 |
| Wei, XD | 1 |
| Mi, RH | 1 |
| Ai, H | 1 |
| Zhang, LN | 1 |
| Liu, YY | 1 |
| Li, YF | 1 |
| Song, YP | 1 |
| Hiramatsu, Y | 1 |
| Maeda, Y | 1 |
| Fujii, N | 1 |
| Saito, T | 2 |
| Nawa, Y | 1 |
| Hara, M | 1 |
| Yano, T | 1 |
| Asakura, S | 1 |
| Sunami, K | 1 |
| Tabayashi, T | 1 |
| Miyata, A | 1 |
| Matsuoka, KI | 1 |
| Shinagawa, K | 1 |
| Ikeda, K | 1 |
| Matsuo, K | 1 |
| Tanimoto, M | 1 |
| Nawrot, U | 1 |
| Nowicka, J | 1 |
| Wlodarczyk, K | 1 |
| Slobbe, L | 1 |
| Waal, Lv | 1 |
| Jongman, LR | 1 |
| Lugtenburg, PJ | 1 |
| Rijnders, BJ | 1 |
| Wang, J | 1 |
| Zhan, P | 1 |
| Zhou, R | 1 |
| Xu, J | 1 |
| Shao, X | 1 |
| Yang, Y | 1 |
| Ouyang, J | 1 |
| Sobrevilla Calvo, P | 1 |
| Sun, J | 1 |
| Qi, C | 1 |
| Lafleur, MD | 1 |
| Qi, QG | 1 |
| Wingard, JR | 1 |
| Carter, SL | 1 |
| Walsh, TJ | 1 |
| Kurtzberg, J | 1 |
| Small, TN | 1 |
| Baden, LR | 1 |
| Gersten, ID | 1 |
| Mendizabal, AM | 1 |
| Leather, HL | 1 |
| Confer, DL | 1 |
| Maziarz, RT | 1 |
| Stadtmauer, EA | 1 |
| Bolaños-Meade, J | 1 |
| Brown, J | 1 |
| Dipersio, JF | 1 |
| Boeckh, M | 1 |
| Marr, KA | 1 |
| Almyroudis, NG | 1 |
| Segal, BH | 1 |
| Schuster, MG | 1 |
| Meibohm, A | 1 |
| Lloyd, L | 1 |
| Strom, B | 1 |
| Zeuli, JD | 1 |
| Wilson, JW | 1 |
| Estes, LL | 1 |
| Westbrook, SD | 1 |
| Kirkpatrick, WR | 1 |
| Wiederhold, NP | 1 |
| Freytes, CO | 1 |
| Toro, JJ | 1 |
| Patterson, TF | 1 |
| Redding, SW | 1 |
| Pagano, L | 1 |
| Fianchi, L | 1 |
| Caramatti, C | 1 |
| D'Antonio, D | 2 |
| Melillo, L | 1 |
| Caira, M | 1 |
| Masini, L | 1 |
| Todeschini, G | 1 |
| Girmenia, C | 2 |
| Martino, B | 1 |
| Cinieri, S | 1 |
| Martino, P | 2 |
| Del Favero, A | 1 |
| Di Bonaventura, G | 1 |
| Spedicato, I | 1 |
| Picciani, C | 1 |
| Piccolomini, R | 1 |
| Minenko, SV | 1 |
| Zhukov, NV | 1 |
| Chimishkian, KL | 1 |
| Sokolova, EN | 1 |
| Ptushkin, VV | 1 |
| Kumar, CP | 1 |
| Sundararajan, T | 1 |
| Menon, T | 1 |
| Venkatadesikalu, M | 1 |
| Glasmacher, A | 4 |
| Prentice, AG | 3 |
| Vardakas, KZ | 1 |
| Michalopoulos, A | 1 |
| Falagas, ME | 1 |
| Bethge, WA | 1 |
| Schmalzing, M | 1 |
| Stuhler, G | 1 |
| Schumacher, U | 2 |
| Kröber, SM | 1 |
| Horger, M | 1 |
| Einsele, H | 2 |
| Kanz, L | 1 |
| Hebart, H | 2 |
| Cornely, O | 1 |
| Ullmann, AJ | 1 |
| Wedding, U | 1 |
| Bodenstein, H | 1 |
| Wandt, H | 1 |
| Boewer, C | 1 |
| Pasold, R | 1 |
| Wolf, HH | 1 |
| Hänel, M | 1 |
| Dölken, G | 1 |
| Junghanss, C | 1 |
| Andreesen, R | 1 |
| Bertz, H | 1 |
| Shen, Q | 1 |
| Song, XM | 1 |
| Xu, XP | 1 |
| Wang, JM | 1 |
| Djulbegovic, B | 1 |
| Myoken, Y | 1 |
| Kyo, T | 1 |
| Sugata, T | 1 |
| Murayama, SY | 1 |
| Mikami, Y | 1 |
| Pazos, C | 1 |
| Moragues, MD | 1 |
| Quindós, G | 1 |
| Pontón, J | 1 |
| del Palacio, A | 1 |
| de Vries, R | 1 |
| Daenen, S | 1 |
| Tolley, K | 1 |
| Prentice, A | 1 |
| Howells, S | 1 |
| Christopherson, H | 1 |
| de Jong-van den Berg, LT | 1 |
| Postma, MJ | 1 |
| Zhu, Y | 1 |
| Chen, SP | 1 |
| Shu, YG | 1 |
| Xu, YJ | 1 |
| Nomura, S | 1 |
| Iishii, K | 1 |
| Inami, N | 1 |
| Kimura, E | 1 |
| Urase, F | 1 |
| Hachem, R | 3 |
| Hanna, H | 1 |
| Kontoyiannis, D | 1 |
| Jiang, Y | 1 |
| Raad, I | 3 |
| Ellis, ME | 1 |
| Spence, D | 1 |
| Ernst, P | 1 |
| Greer, W | 1 |
| Nouwen, JL | 1 |
| van Belkum, A | 1 |
| de Marie, S | 1 |
| Sluijs, J | 1 |
| Wielenga, JJ | 1 |
| Kluytmans, JA | 1 |
| Verbrugh, HA | 1 |
| Takatsuka, H | 1 |
| Takemoto, Y | 1 |
| Okamoto, T | 1 |
| Fujimori, Y | 1 |
| Tamura, S | 1 |
| Wada, H | 1 |
| Okada, M | 1 |
| Kanamaru, A | 1 |
| Kakishita, E | 1 |
| Morgenstern, GR | 1 |
| Prentice, HG | 2 |
| Ropner, JE | 1 |
| Schey, SA | 1 |
| Warnock, DW | 1 |
| Huijgens, PC | 2 |
| Simoons-Smit, AM | 2 |
| van Loenen, AC | 2 |
| Prooy, E | 1 |
| van Tinteren, H | 1 |
| Ossenkoppele, GJ | 1 |
| Jonkhoff, AR | 1 |
| Löffler, J | 1 |
| Hrastnik, C | 1 |
| Daum, G | 1 |
| Jarque, I | 1 |
| Saavedra, S | 1 |
| Martin, G | 1 |
| Pemán, J | 1 |
| Pérez Bellés, C | 1 |
| Sanz, MA | 1 |
| Goranov, S | 1 |
| Spasov, E | 1 |
| Grudeva-Popova, J | 1 |
| Vakrilov, V | 1 |
| Timmers, GJ | 1 |
| Zweegman, S | 1 |
| Touw, D | 1 |
| Böhme, A | 1 |
| Karthaus, M | 1 |
| Hoelzer, D | 1 |
| Salonen, JH | 1 |
| Richardson, MD | 1 |
| Gallacher, K | 1 |
| Issakainen, J | 1 |
| Helenius, H | 1 |
| Lehtonen, OP | 1 |
| Nikoskelainen, J | 1 |
| Tuccinardi, C | 1 |
| Santilli, S | 1 |
| Mondello, F | 1 |
| Monaco, M | 1 |
| Cassone, A | 1 |
| Abbas, J | 1 |
| Bodey, GP | 1 |
| Hanna, HA | 1 |
| Mardani, M | 1 |
| Girgawy, E | 1 |
| Abi-Said, D | 1 |
| Whimbey, E | 1 |
| Trenschel, R | 1 |
| Peceny, R | 1 |
| Runde, V | 1 |
| Elmaagacli, A | 1 |
| Dermoumi, H | 1 |
| Heintschel von Heinegg, E | 1 |
| Müller, KD | 1 |
| Schaefer, UW | 1 |
| Beelen, DW | 1 |
| Paterson, PJ | 1 |
| McWhinney, PH | 1 |
| Potter, M | 1 |
| Kibbler, CC | 1 |
| Minari, A | 1 |
| Kami, M | 2 |
| Sawada, Y | 1 |
| Mori, S | 1 |
| Hirate, J | 1 |
| Kojima, N | 1 |
| Moriya, A | 1 |
| Yuji, K | 1 |
| Chiba, S | 1 |
| Hirai, H | 2 |
| Safdar, A | 1 |
| van Rhee, F | 1 |
| Henslee-Downey, JP | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Machida, U | 1 |
| Okuzumi, K | 1 |
| Matsumura, T | 1 |
| Mori Si, S | 1 |
| Hori, A | 1 |
| Kashima, T | 1 |
| Takaue, Y | 1 |
| Sakamaki, H | 1 |
| Yoneyama, A | 1 |
| Mutou, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)[NCT00075803] | Phase 3 | 600 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone[NCT01553214] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00075803)
Timeframe: day 42
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 11 |
| Voriconazole | 9 |
Incidence of proven, probably, or presumptive IFI (NCT00075803)
Timeframe: 1 year
| Intervention | percentage of patients (Number) |
|---|---|
| Fluconazole | 13.7 |
| Voriconazole | 12.7 |
(NCT00075803)
Timeframe: 1 year
| Intervention | percentage of patients (Number) |
|---|---|
| Fluconazole | 30.2 |
| Voriconazole | 24.1 |
(NCT00075803)
Timeframe: 180 days
| Intervention | percentage of patients (Number) |
|---|---|
| Fluconazole | 74.9 |
| Voriconazole | 78.2 |
(NCT00075803)
Timeframe: 180 days
| Intervention | days (Mean) | ||
|---|---|---|---|
| Number of days on study drug | Start day of empiric antifungal therapy | Days of empiric antifungal therapy | |
| Fluconazole | 91 | 16 | 7 |
| Voriconazole | 96 | 12 | 7 |
(NCT00075803)
Timeframe: 1 year
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| IFI after relapse/progression | IFI before engraftment | IFI who had failure to engraft | IFI after aGVHD (grades II-IV) | IFI while on study drug (up to day 100) | IFI after premature withdrawal of study drug | IFI after start other prophylaxis (not study drug) | IFI after empiric therapy | |
| Fluconazole | 2 | 12 | 2 | 11 | 19 | 11 | 8 | 13 |
| Voriconazole | 8 | 8 | 1 | 14 | 10 | 16 | 11 | 12 |
(NCT00075803)
Timeframe: 100, 180, and 365 days
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| 100 days | 180 days | 365 days | |
| Fluconazole | 85.4 | 80.0 | 70.2 |
| Voriconazole | 90.1 | 81.2 | 67.8 |
(NCT00075803)
Timeframe: 100, 180, and 365 days
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| 100 days | 180 days | 365 days | |
| Fluconazole | 9.5 | 11.2 | 13.7 |
| Voriconazole | 5.6 | 7.3 | 12.7 |
(NCT00075803)
Timeframe: 100, 180, and 365 days
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| 100 days | 180 days | 365 days | |
| Fluconazole | 83.1 | 74.9 | 63.3 |
| Voriconazole | 86.1 | 73.9 | 61.2 |
(NCT00075803)
Timeframe: 100 and 365 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Acute GVHD grade II-IV at day 100 | Acute GVHD grade III-IV at day 100 | Chronic GVHD at 1 year | |
| Fluconazole | 132 | 42 | 138 |
| Voriconazole | 116 | 27 | 137 |
Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives. (NCT00075803)
Timeframe: 1 year
| Intervention | participants (Number) | |
|---|---|---|
| GM+ | GM- | |
| Fluconazole | 43 | 252 |
| Voriconazole | 35 | 270 |
9 reviews available for fluconazole and Hematologic Malignancies
| Article | Year |
|---|---|
Breakthrough invasive fungal infections: Who is at risk?
Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillus; Candida; Central Venous Catheters; Echinoca | 2020 |
[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
Topics: Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses | 2017 |
Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; | 2010 |
[Fungal infections in oncohematology: the role of prophylaxis].
Topics: Antifungal Agents; Antineoplastic Agents; Fever; Fluconazole; Hematologic Neoplasms; Humans; Mycoses | 2010 |
Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Clinical Trials as Topic; Echinocandins; Fluconazole; Hem | 2010 |
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses | 2005 |
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Topics: Antifungal Agents; Chi-Square Distribution; Fluconazole; Hematologic Neoplasms; Hematopoietic Stem C | 2005 |
In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Topics: Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses; Opportunistic | 2006 |
Antifungal prophylaxis in neutropenic patients with hematologic malignancies.
Topics: Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Fluconaz | 2000 |
14 trials available for fluconazole and Hematologic Malignancies
| Article | Year |
|---|---|
Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.
Topics: Adolescent; Adult; Aged; Body Weight; Child; Child, Preschool; Cyclosporine; Dose-Response Relations | 2019 |
D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
Topics: Adult; Aged; Antifungal Agents; Febrile Neutropenia; Female; Fluconazole; Hematologic Neoplasms; Hem | 2020 |
Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluconazole; Hematologic Neoplasms; Humans; | 2014 |
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Echinocandins; Female; Fluconazole; Hematologic Neoplasm | 2008 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Endpoint Determinati | 2006 |
Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anemia, Aplastic; Antibodies, Fungal; Antibody Specificity; | 2006 |
Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Female; Fluconazole; | 1999 |
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents, Phytogenic; Drug Interactions; Fe | 1999 |
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Fluconazole; Hematologic Neoplasms; Hem | 1999 |
Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Hematologic Neoplasms; Humans; Male; Middle Aged; Myc | 1999 |
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
Topics: Adolescent; Adult; Aged; Amphotericin B; Bilirubin; Consumer Product Safety; Contraindications; Fema | 2000 |
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; | 2000 |
Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy.
Topics: Adult; Age Factors; Antifungal Agents; Antineoplastic Agents; Aspartate Aminotransferases; Dose-Resp | 2001 |
33 other studies available for fluconazole and Hematologic Malignancies
| Article | Year |
|---|---|
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Drug Resis | 2008 |
Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; China; Cost-Benefit Analysis; Female; Fluconazole | 2018 |
Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Algorithms; Antifungal Agents; Azoles; Drug Dosage Calculations; Female; Fluconazole; H | 2015 |
Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis.
Topics: Adult; Antifungal Agents; Candida; Candidemia; Candidiasis, Invasive; Drug Resistance, Fungal; Femal | 2014 |
[A clinical study of fungal esophagitis in 13 patients with hematologic malignancies].
Topics: Esophagitis; Fluconazole; Hematologic Neoplasms; Humans; Mycoses; Prognosis; Retrospective Studies; | 2016 |
Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hematologic Neoplasms | 2008 |
Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; An | 2009 |
Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Oral; China; DNA, F | 2009 |
Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study.
Topics: Adult; Aged; Antifungal Agents; Blood; Candida; Candidemia; Case-Control Studies; Culture Media; Dru | 2013 |
Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Topics: Adult; Aged; Antifungal Agents; Drug Administration Schedule; Drug Therapy, Combination; Electrocard | 2013 |
Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Candida; Candida albicans; Candida glab | 2013 |
Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Cryptococcosis; Female; Fluconazole; Hematologic Neoplas | 2004 |
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Echin | 2004 |
[Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hema | 2004 |
Candidosis in children with onco-hematological diseases in Chennai, south India.
Topics: Antifungal Agents; Candida; Candidiasis; Child; Cohort Studies; Drug Resistance, Fungal; Female; Flu | 2005 |
Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Communicable Diseases, Emergi | 2005 |
[Pulmonary fungal infection in malignant hematological diseases: an analysis of 14 cases].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol | 2005 |
Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Topics: Candida albicans; Candidiasis; Drug Resistance; Fluconazole; Fungemia; Hematologic Neoplasms; Humans | 2006 |
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cost-Benefit Analysis; Female; Fl | 2008 |
[Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol | 2008 |
Elevation of activated platelet-dependent chemokines and soluble cell adhesion molecules in patients with hematologic malignancies and high levels of beta-D-glucan.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; b | 2007 |
The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Catheterization, Central Venous; Cohort Stu | 2008 |
Variability of plasma fluconazole levels in patients with hematologic malignancy.
Topics: Alanine Transaminase; Antifungal Agents; Bilirubin; Candidiasis; Drug Interactions; Female; Fluconaz | 1997 |
Clonal expansion of Staphylococcus epidermidis strains causing Hickman catheter-related infections in a hemato-oncologic department.
Topics: Air Microbiology; Antibiotic Prophylaxis; Bacteriological Techniques; Catheterization, Central Venou | 1998 |
Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Cell Membra | 2000 |
Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole.
Topics: Antifungal Agents; Candidiasis; Female; Fluconazole; Fungemia; Hematologic Neoplasms; Humans; Male; | 2000 |
Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; | 2000 |
In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Fluconazole; Hematologic Neoplasms; Humans; Microb | 2000 |
Candida krusei fungemia. An escalating serious infection in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Agents | 2000 |
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Bone Marrow Transplantation; Candida; Candidiasis; Drug R | 2001 |
Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Candida; Candidiasis; D | 2001 |
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Topics: Adolescent; Adult; Antifungal Agents; Bacteremia; Bone Marrow Transplantation; Candida; Candidiasis; | 2001 |
Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Autopsy; Candidiasis; | 2002 |